Join us in revolutionizing incontinence treatment
InControl Medical is the leading provider of at-home FDA cleared medical devices for the treatment of incontinence in women. Bladder leakage affects 60 million women in the United States and bowel leakage affects an additional 16 million women.
In 90% of cases, bladder leakage is a muscle issue and InControl has worked to solve the issue without using pads, medications, or surgery. To date, InControl products have helped over 170,000 customers, with an over 90% effective cure rate.
InControl recently became certified by Medicare to sell and bill directly to Medicare. InControl Medical is poised to become the standard of care for urinary and fecal incontinence in the US.
Simply return the above noted documents to us at the following address:
InControl Medical, LLC, c/o Foley & Lardner LLP, 777 E. Wisconsin Ave., Milwaukee, WI 53202, Attn: David Seno.
Payments may be remitted via a personal check payable to “InControl Medical, LLC Security Account” for the dollar amount of your investment, or sent via wire transfer
Bank Name: First Midwest Bank Bank Address: 14870 W Greenfield Ave, Brookfield, WI 53005 Phone #: 414-466-8000 Routing #: 071901604 Account #: 8100746760
The account name is: InControl Medical, LLC Security Account
Learn more about our InControl, our mission to eliminate bladder leakage as a factor in women’s lives, and the opportunity to invest.
Scheduling is self serve, and attendance is limited to first-come, first served. Minimum investment is $50,000.00
Fill out the form below, and our executive team will get in touch to answer your questions personally.
The statements above are for informational purposes only and do not constitute an “offer” or a “solicitation of an offer” to sell securities. Such an offer or solicitation of an offer can only be made through the Company’s private placement memorandum. The Company’s membership units have not been and will not be registered under the Securities Act of 1933, as amended, or applicable state securities laws nor the securities laws of any other jurisdiction, in each case in reliance upon exemptions from such registration provided by the Securities Act of 1933, as amended, and Regulation D Rule 506(c) and the comparable exemptions from registration provided by other applicable securities laws. As a result, the Company’s private placement memorandum is not required to comply with specific disclosure requirements that apply to registration under the Securities Act. Neither the U.S. Securities and Exchange Commission nor any other regulatory authority has passed upon the merits of, or given its approval to, the Company’s common membership units, the terms of the Company’s private placement, or the accuracy or completeness of the Company’s private placement memorandum or any offering materials. The Company’s common membership units offered by the Company’s private placement memorandum are restricted securities subject to specific restrictions on transferability and resale, are highly illiquid and are subject to significant risk. Investors should not assume they will be able to resell the Company’s common membership units and investors must be able to bear the risk of loss of their entire investment. Only accredited investors, as defined under applicable securities laws, will be allowed to purchase the Company’s common membership units, which for natural persons, are investors who meet certain minimum annual income or net worth thresholds or other requirements.
You have questions, our clinicians have answers. Not sure about the cause or treatments available for your bladder leakage? We’re here to help.
© 2021 InControl Medical.